Novo Nordisk (NVO) earnings Q4, Ministry of Finance for the whole year

Shares Novo Nordisk Ross reported more than expected net profit in the fourth quarter after it reported a surge in demand for Wegovy obesity drugs, but forecasts a slight decline in sales in 2025.

Danish Pharmaceutical Behemoth's net profit increased by 29% per year to 28.23 billion Denmark Krona (US$3.98 billion), while Danish Kroner expects 26.09 billion times.

Net profit for the full year rose 21% to 100.9 billion Denmark Krona, also defeating the Danish clones 99.14 billion times in 2024.

stock Trading with slight gain 4.18% gained at 9:00 am London time.

Drug Manufacturers Release 107Percent In the three months to the end of December, analysts' forecasts were slightly higher than the Danish Kroner ($2.76 billion) late Tuesday, down to 19.87 billion Delhi Krona ($2.76 billion) , in a fact-based poll late Tuesday, DKK sales increased year-on-year to 19.87 billion Denmark Krona ($2.76 billion).

The company's overall sales, which also produces diabetes and rare diseases, grew 30% in the fourth quarter and 26% at a sustained exchange rate. This growth is driven primarily by demand in North America, Europe, the Middle East and Africa.

However, Novo Nordisk's forecast, sales growth in 2025 slowed down by 2025 at the ongoing exchange rate, down from the 18% to 26% forecast in 2024. The company said the forecast reflects the “intensifying competition and continuing stress on the diabetes and obesity care market”.

Susannah Streeter, head of currency and markets at Hargreaves Lansdown, said the wide range of guidance suggests that Novo Nordisk's current market share could slow. She added that obesity medications still have a “long way to go” given its wide range of health benefits.

“Further acceleration will depend on more extended use cases approved by health regulators,” she added.

Novo Nordisk is growing, and global demand for GLP-1 agonist obesity treatments continues to rise. GLP-1, the basis for Novo's Wegovy and competitors YililaiZepbound, works by mimicking a hormone called glucagon peptide 1, which suppresses appetite.

Now, investors are following the latest information on the company’s other obesity drug candidates, including its highly anticipated experimental anger therapy. Later results of the angry disease trial in December showed an average weight loss of 22.7%, below 25% of Novo's previous forecast, which disappointed the December market.

The results of the trial hit expectations that cagrisema will become Novo's next-generation obesity drug, combining Semaglutide (the active ingredient in Wegovy) with Amylin Analog cagrilintide, a new form of weight loss treatment.

However, last month, it used to use amylase pancreatic hormone positive early results for a positive amygdala obesity drug, which was stocked higher last month.

Novo Nordisk said Wednesday it will conduct further research on Cagrisema in 2025 with a view to applying for regulatory approval in the first quarter of 2026.